PMID- 22526543 OWN - NLM STAT- MEDLINE DCOM- 20131028 LR - 20211021 IS - 1432-2072 (Electronic) IS - 0033-3158 (Print) IS - 0033-3158 (Linking) VI - 226 IP - 4 DP - 2013 Apr TI - Effects of the kappa opioid receptor antagonist, norbinaltorphimine, on stress and drug-induced reinstatement of nicotine-conditioned place preference in mice. PG - 763-8 LID - 10.1007/s00213-012-2716-y [doi] AB - RATIONALE: Several studies implicate stress as a risk factor for the development and maintenance of drug addictive behaviors and drug relapse. Kappa opioid receptor (KOR) antagonists have been shown to attenuate behavioral responses to stress and stress-induced reinstatement of cocaine and ethanol seeking and preference. OBJECTIVES: In the current study, we determined whether the selective KOR antagonist, norbinaltorphimine (nor-BNI), would block stress-induced reinstatement of nicotine preference. METHODS: Adult Institute of Cancer Research mice were conditioned with 0.5 mg/kg nicotine, injected subcutaneously (s.c.) for 3 days and tested in the nicotine-conditioned place preference (CPP) model. After 3 days extinction, nor-BNI (10 mg/kg, s.c.) was administered 16 h prior to a priming dose of nicotine (0.1 mg/kg, s.c.), and mice were tested in the CPP model for nicotine-induced reinstatement of CPP. A separate group of mice was subjected to a 2-day modified forced swim test (FST) paradigm to induce stress after 3 days extinction from CPP. Mice were given vehicle or nor-BNI (10 mg/kg, s.c.) 16 h prior to each FST session. RESULTS: Nor-BNI pretreatment significantly attenuated stress-induced reinstatement of nicotine-CPP, but had no effect on nicotine-primed reinstatement. CONCLUSIONS: Blockade of KORs by selective antagonists attenuates stress-induced reinstatement of nicotine-CPP. Overall, the kappa opioid system may serve as a therapeutic target for suppressing multiple signaling processes which contribute to maintenance of smoking, smoking relapse, and drug abuse in general. FAU - Jackson, K J AU - Jackson KJ AD - Department of Psychiatry, Virginia Commonwealth University, Richmond, VA 23219, USA. FAU - McLaughlin, J P AU - McLaughlin JP FAU - Carroll, F I AU - Carroll FI FAU - Damaj, M I AU - Damaj MI LA - eng GR - R01 DA012610/DA/NIDA NIH HHS/United States GR - T32 MH020030/MH/NIMH NIH HHS/United States GR - MH-020030/MH/NIMH NIH HHS/United States GR - DA-12610/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20120420 PL - Germany TA - Psychopharmacology (Berl) JT - Psychopharmacology JID - 7608025 RN - 0 (Narcotic Antagonists) RN - 0 (Receptors, Opioid, kappa) RN - 36OOQ86QM1 (norbinaltorphimine) RN - 5S6W795CQM (Naltrexone) RN - 6M3C89ZY6R (Nicotine) SB - IM MH - Animals MH - Conditioning, Psychological/drug effects MH - Disease Models, Animal MH - Extinction, Psychological MH - Male MH - Mice MH - Mice, Inbred ICR MH - Naltrexone/*analogs & derivatives/pharmacology MH - Narcotic Antagonists/*pharmacology MH - Nicotine/*administration & dosage MH - Receptors, Opioid, kappa/antagonists & inhibitors MH - Recurrence MH - Risk Factors MH - Self Administration MH - Smoking/epidemiology MH - Stress, Psychological/*psychology PMC - PMC3821839 MID - NIHMS522968 COIS- Conflict of interest There are no conflicts of interest to disclose for this research. The experiments in the current studies comply with the current laws in the country in which they were performed. EDAT- 2012/04/25 06:00 MHDA- 2013/10/29 06:00 PMCR- 2013/11/08 CRDT- 2012/04/25 06:00 PHST- 2012/02/04 00:00 [received] PHST- 2012/03/31 00:00 [accepted] PHST- 2012/04/25 06:00 [entrez] PHST- 2012/04/25 06:00 [pubmed] PHST- 2013/10/29 06:00 [medline] PHST- 2013/11/08 00:00 [pmc-release] AID - 10.1007/s00213-012-2716-y [doi] PST - ppublish SO - Psychopharmacology (Berl). 2013 Apr;226(4):763-8. doi: 10.1007/s00213-012-2716-y. Epub 2012 Apr 20.